Clinical trials: Intestine
Autism Spectrum Disorder
Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder
The purpose of this study is to assess the effects of 3 months supplementation with the multi strain probiotic Vivomixx on the overall function, aberrant behaviours and frequency of gastrointestinal symptoms in children with…
- Trial name
- VIVO-ASD (NCT03369431)
- Testing
- Vivomixx
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- University College, London
Rectal Cancer, Colo-rectal Cancer
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
The objectives of this study are to: 1. To assess dose-limiting toxicities (DLTs) of capecitabine +/- oxaliplatin in a combination regimen with capecitabine and radiotherapy (Phase 1) 2.
- Trial name
- NCT00226941
- Testing
- Cetuximab, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- George Albert Fisher
Colorectal Cancer
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
- Trial name
- NCT01719380
- Testing
- LGX818, Cetuximab, BYL719
- Where
- 52 sites in United States, Australia and 10 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Colorectal Cancer
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
- Trial name
- GEN206 (NCT00677924)
- Testing
- Zalutumumab
- Where
- 3 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Genmab
Ulcerative Colitis
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
As required for new medications approved by the Ministry of Food and Drug Safety, safety and efficacy information should be provided for a minimum of 90 patients treated in the setting of routine practice during 4 years following…
- Trial name
- NCT04071405
- Testing
- Non-intervention
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Inflammatory Arthritis
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor…
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis
- Trial name
- NCT02538341
- Testing
- Herpes Zoster (HZ) Vaccine
- Where
- 34 sites in United States
- Volunteers
- 617 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Crohn's Disease
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension.
- Trial name
- NCT02405442
- Testing
- Andecaliximab
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 187 people
- Sponsor
- Gilead Sciences
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Crohn's Disease, Inflammatory Bowel Disease
Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
Crohn's disease is an inflammatory disorder that can affect any part of the gastrointestinal (GI) tract. Some patients still experience persistent diarrhea or other symptoms such as abdominal pain even when their Crohn's disease…
- Trial name
- REACT (NCT04456517)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Colorectal Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112918
- Testing
- Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 3,451 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease
Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed…
- Trial name
- NCT01349920
- Testing
- Infliximab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenomatous Polyposis Coli
Sirolimus and Familial Adenomatous Polyposis (FAP)
The aim of the study is to investigate the effect of sirolimus on the progression of intestinal adenomas in patients with FAP and to assess the safety of this treatment.
- Trial name
- NCT03095703
- Testing
- Sirolimus
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Many people with Cystic Fibrosis (CF) are troubled by symptoms from their stomach and bowels: their gastrointestinal (GI) tract.
- Trial name
- GIFT-CF1 (NCT03566550)
- Testing
- MRI scans
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Colorectal Neoplasms
TAS-OX for Refractory Metastatic Colon Cancer
This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX…
- Trial name
- NCT02848079
- Testing
- combined TAS-102 and TAS-OX
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Crohn Disease
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
This open-label extension and safety monitoring study is composed of two parts: Part 1 will evaluate the long-term safety and efficacy of continued etrolizumab treatment in participants with moderately to severely active Crohn's…
- Trial name
- JUNIPER (NCT02403323)
- Testing
- Etrolizumab
- Where
- 287 sites in United States, Argentina and 31 more
- Volunteers
- 790 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
- Trial name
- EMERALD-1 (NCT05291689)
- Testing
- MORF-057
- Where
- 17 sites in United States, Poland
- Volunteers
- 39 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Anal Cancer, Precancerous Condition
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
RATIONALE: High-grade squamous intraepithelial lesions of the skin near the anus are caused by the human papillomavirus (HPV). Antiviral drugs,, such as cidofovir, act against viruses and may stop these lesions from becoming…
- Trial name
- NCT00550589
- Testing
- cidofovir, DNA methylation analysis, gene expression analysis
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- AIDS Malignancy Consortium
Type 3 Von Willebrand's Disease
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand…
- Trial name
- 3WINTERS-IPS (NCT02460458)
- Testing
- Von Willebrand Factor
- Where
- 25 sites in Finland, France and 8 more
- Volunteers
- 265 people
- Sponsor
- Fondazione Angelo Bianchi Bonomi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.